摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-nitro-thiophenol potassium salt | 71367-29-8

中文名称
——
中文别名
——
英文名称
4-nitro-thiophenol potassium salt
英文别名
K(p-SC6H4NO2);potassium 4-nitrophenylthiolate;4-nitro-benzenethiol; potassium salt;potassium (4-nitrophenyl)sulfide;potassium 4-nitrothiophenolate;Potassium;4-nitrobenzenethiolate
4-nitro-thiophenol potassium salt化学式
CAS
71367-29-8
化学式
C6H4NO2S*K
mdl
——
分子量
193.268
InChiKey
INFNXSSRRJMZAM-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.5
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    46.8
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:2e24d8e9553c1e56e1e6c1953106992f
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Therapeutic amides
    申请人:Imperial Chemical Industries PLC
    公开号:US05272163A1
    公开(公告)日:1993-12-21
    Amides having formula I: ##STR1## wherein E, X, R.sup.2 and R.sup.3 have the meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable in vivo hydrolysable esters thereof, which are useful in the treatment of urinary incontinence. Further provided are processes for preparing the amides and pharmaceutical compositions containing them.
    酰胺具有以下化学式I:##STR1## 其中E、X、R.sup.2和R.sup.3的含义如规范中所述,并且其药学上可接受的盐和在体内可水解的酯,可用于治疗尿失禁。还提供了制备这些酰胺的方法和含有它们的药物组合物。
  • Benzosulfone derivatives
    申请人:Hoffmann-La Roche Inc.
    公开号:US05990105A1
    公开(公告)日:1999-11-23
    The present invention relates to novel compounds of the general formula ##STR1## wherein R.sup.1 is hydrogen; R.sup.2 is hydrogen, trifluoromethyl or lower alkyl; R.sup.3 is hydrogen or amino; or R.sup.1 and R.sup.2 or R.sup.3 and R.sup.2 taken together are --CH.dbd.CH--CH.dbd.CH--; Z is pyrimidin-4-yl, pyridin-4-yl, pyridin-2-yl or phenyl; R.sup.4, R.sup.5 are each independently hydrogen, lower alkyl, trifluoromethyl, halogen, lower alkoxy, nitrilo, amino, lower alkyl-amino, di-lower alkyl-amino, piperazinyl, morpholinyl, pyrrolidinyl, vinyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.3 -C.sub.6 cycloalkenyl, t-buthylethinyl, hydroxyalkylethinyl, phenylethinyl, naphthyl, thiophenyl, or phenyl, which may be substituted by halogen, lower alkoxy, lower alkyl, trifluoromethyl or nitro, or a group --NH(CH.sub.2).sub.n NR.sup.6 R.sup.7, --N(CH.sub.3)(CH.sub.2).sub.n NR.sup.6 R.sup.7, --NH(CH.sub.2).sub.n -morpholin-4-yl or --NH(CH.sub.2).sub.n OH; n is 2-4 R.sup.6 and R.sup.7 are each independently hydrogen or lower alkyl, and to their pharmaceutically acceptable salts. It has been found that the compounds of formula I possess a selective affinity to 5HT-6 receptors.
    本发明涉及一般式为##STR1##的新化合物,其中R.sup.1为氢;R.sup.2为氢,三氟甲基或较低的烷基;R.sup.3为氢或氨基;或者R.sup.1和R.sup.2或R.sup.3和R.sup.2一起取--CH.dbd.CH--CH.dbd.CH--;Z为嘧啶-4-基,吡啶-4-基,吡啶-2-基或苯基;R.sup.4,R.sup.5各自独立地为氢,较低烷基,三氟甲基,卤素,较低烷氧基,氰基,氨基,较低烷基氨基,二较低烷基氨基,哌嗪基,吗啉基,吡咯烷基,乙烯基,C.sub.3 -C.sub.6环烷基,C.sub.3 -C.sub.6环烯基,叔丁基乙炔基,羟基烯基,苯基乙炔基,萘基,噻吩基或苯基,可以被卤素,较低烷氧基,较低烷基,三氟甲基或硝基取代,或者为--NH(CH.sub.2).sub.n NR.sup.6 R.sup.7,--N(CH.sub.3)(CH.sub.2).sub.n NR.sup.6 R.sup.7,--NH(CH.sub.2).sub.n -吗啉-4-基或--NH(CH.sub.2).sub.n OH的基团;n为2-4,R.sup.6和R.sup.7各自独立地为氢或较低烷基,以及它们的药用可接受盐。已发现,式I的化合物具有对5HT-6受体的选择性亲和力。
  • New mono- and bis(pentafluorophenyl)palladium(II) complexes with iminophosphine ligands. Crystal structure of [Pd(C6F5)(SC6H5)(o-Ph2PC6H4–CHNiPr)]
    作者:Gregorio Sánchez、José L. Serrano、Francisca Momblona、Francisco Ruiz、Joaquı́n Garcı́a、José Pérez、Gregorio López、Penny A. Chaloner、Peter Hitchcock
    DOI:10.1016/s0277-5387(00)00659-8
    日期:2001.3
    between the labile precursors cis-[Pd(C6F5)2(PhCN)2] or [Pd(C6F5)(tht)(μ-Cl)}2] (tht=tetrahydrothiophene) and the corresponding iminophosphines. Complex (9) undergoes metathetical exchange of chloride with anionic monodentate ligands when reacting with alkaline salts, giving the complexes of formula [Pd(C6F5)X(iPrN–P)] [X=Br (11), I (12), CN (13), SCN (14), SC6H5 (15), p-SC6H4Me (16), p-SC6H4NO2 (17),
    摘要:合成了具有混合给体双齿配体o-Ph2PC6H4-CHNR(RN-P)的钯(II)单和双(五氟苯基)衍生物。通式为[Pd(C6F5)2(RN–P)]的新络合物[R = Me(1),Et(2),nPr(3)iPr(4),tBu(5),Ph(6), NH–Me(7)]和[Pd(C6F5)Cl(RN–P)] [R = Me(8),iPr(9),NH–Me(10)]分别通过不稳定的前体顺式[[Pd(C6F5)2(PhCN)2]或[Pd(C6F5)(tht)(μ-Cl)} 2](tht =四氢噻吩)和相应的亚氨基膦。与碱金属盐反应时,配合物(9)与阴离子单齿配体进行氯离子交换,得到式[Pd(C6F5)X(iPrN–P)]的配合物[X = Br(11),I(12),CN (13),SCN(14),SC6H5(15),p-SC6H4Me(16),p-SC6H4NO2(17),OMe(18)]。此
  • Organometallic Nickel(II) Complexes Containing Thiolate and Dithiocarbamate Ligands
    作者:Gregorio Sánchez、Francisco Ruiz、José L. Serrano、M. Carmen Ramírez de Arellano、Gregorio López
    DOI:10.1002/1099-0682(200010)2000:10<2185::aid-ejic2185>3.0.co;2-k
    日期:2000.10
    mono(pentafluorophenyl)nickel(II) complexes [Ni(C6F5)ClL2] (L = PPhMe2, PPh2Me; L2 = dppe) react with KSR (R = Ph, C6H4Me-p, C6H4OMe-p, C6H4Cl-p, C6H3Cl22,6, C6H4NO2-p) at room temperature in acetone/dichloromethane to give the mononuclear thiolate complexes [Ni(C6F5)(SR)L2]. The binuclear μ-thiolate complex [Ni(C6F5)(PPhMe2)}2(μ-SC6H4NO2-p)2] is obtained by reaction of KSC6H4NO2-p with the same chloro complex in refluxing
    单(五氟苯基)镍(II)配合物 [Ni(C6F5)ClL2] (L = PPhMe2, PPh2Me; L2 = dppe) 与 KSR (R = Ph, C6H4Me-p, C6H4OMe-p, C6H4Cl-p, C6H3Cl22, 6, C6H4NO2-p) 在室温下在丙酮/二氯甲烷中得到单核硫醇盐络合物 [Ni(C6F5)(SR)L2]。双核μ-硫醇盐络合物[Ni(C6F5)(PPhMe2)}2(μ-SC6H4NO2-p)2]是通过KSC6H4NO2-p与相同的氯络合物在回流二氯甲烷中反应得到的。[Ni(C6F5)(SC6H4NO2-p)(PPhMe2)2] 和 [Ni2(C6F5)2(PPhMe2)2(μ-SC6H4NO2-p)2] 的单晶 X 射线衍射研究已经建立了单核和复合物的双核性质。迪-
  • Luminescent Gold(I) and Copper(I) Phosphane Complexes Containing the 4‐Nitrophenylthiolate Ligand: Observation of π→π* Charge‐Transfer Emission
    作者:Cheng‐Hui Li、Steven Chi Fai Kui、Iona Hiu Tung Sham、Stephen Sin‐Yin Chui、Chi‐Ming Che
    DOI:10.1002/ejic.200700675
    日期:2008.5
    Gold(I) and copper(I) phosphane complexes containing the 4-nitrophenylthiolate ligand, namely [(PCy 3 )Au(SC 6 H 4 NO 2 -4)] (1) (PCy 3 = tricyclohexylphosphane), [Au 2 (μ-dcpm)-(SC 6 H 4 NO 2 -4) 2 ] (2) [dcpm = bis(dicyclohexylphosphanyl)-methane], [Au2(μ-dppm)(SC 6 H 4 NΟ 2 -4)2] (3) [dppm = bis(diphenylphosphanyl)methane], and [(μ 2 -SC 6 H 4 NO 2 -4) 2 (μ 3 -SC 6 H 4 NO 2 -4)2(CuPPh3) 4 ] (4)
    含有 4-硝基苯硫醇配体的金 (I) 和铜 (I) 磷烷配合物,即 [(PCy 3 )Au(SC 6 H 4 NO 2 -4)] (1) (PCy 3 = 三环己基膦),[Au 2 ( μ-dcpm)-(SC 6 H 4 NO 2 -4) 2 ] (2) [dcpm = 双(二环己基膦酰基)-甲烷],[Au2(μ-dppm)(SC 6 H 4 N0 2 -4)2] (3) [dppm = 双(二苯基膦酰基)甲烷],和 [(μ 2 -SC 6 H 4 NO 2 -4) 2 (μ 3 -SC 6 H 4 NO 2 -4)2(CuPPh3) 4 ] (4 ),通过 X 射线晶体分析制备和表征。所有这些复合物都显示出强吸收带,λ max 在 396-409 nm 处归因于配体 (IL) π(S)→π*(C 6 H 4 NO 2 -4) 电荷转移跃迁。模型复合物 [PH 3 Au(SC 6 H 4 NO
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐